Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Quintino Giorgio D’Alessandris; Nicola Montano; Maurizio Martini; Tonia Cenci; Liverana Lauretti; Vittorio Stumpo; Fabrizio Pignotti; Alessandro Olivi; Eduardo Fernandez; Luigi Maria Larocca; Roberto Pallini

doi:10.1007/s00701-018-3697-3

Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Quintino Giorgio D’Alessandris, Nicola Montano, Maurizio Martini, Tonia Cenci, Liverana Lauretti, Vittorio Stumpo, Fabrizio Pignotti, Alessandro Olivi, Eduardo Fernandez, Luigi Maria Larocca, Roberto Pallini

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

Original language	English (US)
Pages (from-to)	2387-2391
Number of pages	5
Journal	Acta Neurochirurgica
Volume	160
Issue number	12
DOIs	https://doi.org/10.1007/s00701-018-3697-3
State	Published - Dec 2018
Externally published	Yes

Keywords

Bevacizumab
Erlotinib
Glioblastoma
Tailored therapy
Targeted therapy

ASJC Scopus subject areas

Surgery
Clinical Neurology

Access to Document

10.1007/s00701-018-3697-3

Cite this

@article{8098cdc018a64e0c955f2742fd4e46ad,

title = "Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report",

abstract = "Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.",

keywords = "Bevacizumab, Erlotinib, Glioblastoma, Tailored therapy, Targeted therapy",

author = "D{\textquoteright}Alessandris, {Quintino Giorgio} and Nicola Montano and Maurizio Martini and Tonia Cenci and Liverana Lauretti and Vittorio Stumpo and Fabrizio Pignotti and Alessandro Olivi and Eduardo Fernandez and Larocca, {Luigi Maria} and Roberto Pallini",

note = "Funding Information: The authors thank the Head Nurse, Giovanna Farisei, and all the nurses of the Department of Neurosurgery of Fondazione Policlinico Universitario A. Gemelli IRCCS for their invaluable work in giving care to GBM patients. Publisher Copyright: {\textcopyright} Springer-Verlag GmbH Austria, part of Springer Nature 2018.",

year = "2018",

month = dec,

doi = "10.1007/s00701-018-3697-3",

language = "English (US)",

volume = "160",

pages = "2387--2391",

journal = "Acta Neurochirurgica",

issn = "0001-6268",

publisher = "Springer Wien",

number = "12",

}

TY - JOUR

T1 - Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy

T2 - a case report

AU - D’Alessandris, Quintino Giorgio

AU - Montano, Nicola

AU - Martini, Maurizio

AU - Cenci, Tonia

AU - Lauretti, Liverana

AU - Stumpo, Vittorio

AU - Pignotti, Fabrizio

AU - Olivi, Alessandro

AU - Fernandez, Eduardo

AU - Larocca, Luigi Maria

AU - Pallini, Roberto

N1 - Funding Information: The authors thank the Head Nurse, Giovanna Farisei, and all the nurses of the Department of Neurosurgery of Fondazione Policlinico Universitario A. Gemelli IRCCS for their invaluable work in giving care to GBM patients. Publisher Copyright: © Springer-Verlag GmbH Austria, part of Springer Nature 2018.

PY - 2018/12

Y1 - 2018/12

N2 - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

AB - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

KW - Bevacizumab

KW - Erlotinib

KW - Glioblastoma

KW - Tailored therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85055184229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055184229&partnerID=8YFLogxK

U2 - 10.1007/s00701-018-3697-3

DO - 10.1007/s00701-018-3697-3

M3 - Article

C2 - 30306271

AN - SCOPUS:85055184229

SN - 0001-6268

VL - 160

SP - 2387

EP - 2391

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

IS - 12

ER -

Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this